­
­
­
­

Inventi Impact - Oncology
(Formerly Inventi Rapid/Impact: Cancer)

Articles

  • Inventi:hoc/22715/17
    ASSESSMENT OF ANTICANCER PROPERTIES OF GRAPE SEED DERIVED PROCYANIDIN AND QUERCETIN AGAINST LUNG (A549) AND PROSTATE (PC-3) CANCER CELL LINES: AN IN-VITRO STUDY
    Marina Fakhry*, Aly Fahmy Mohamed, Eman Amin Ismail

    The aim of the present study was to verify the anti-cancer potentials of quercetin and procyanidin derived from grape seed against (PC-3) human prostate cancer cells and (A549) human lung cancer cells. Cytotoxicity potential of test products was assessed using MTT assay. Data recorded revealed that the IC50 was cell type and concentration dependent, where quercetin was significantly effective against A549 than PC-3 cells. Also, procyanidin and quercetin mix showed a significant antagonistic reactivity in both cell lines compared with the single use of test products. Also, GSE derived procyanidin showed a lower toxicity to test A549 cells and significantly decreased IC50 value to PC-3 cell line (P<0.05). Regarding the cell cycle profile of treated cancer cells, data revealed that cell cycle was mainly arrested at G2-M phase post cell treatment accompanied with significant apoptotic profile in the pre G1-phase. Moreover, the pro-apoptotic and anti-apoptotic genes were monitored in quercetin and procyanidin treated cells using real-time PCR. It was noticed that pro-apoptotic genes (Bax and P53) were up-regulated significantly to the cell control accompanied with down regulation of anti-apoptotic gene (Bcl-2). Collectively, our observations demonstrated that procyanidin and quercetin have an anti-cancer potential against PC-3 and A549 cells Also, synergistic potential was detected in case of using quercetin and procyanidin mix.

    How to Cite this Article
    Marina Fakhry, Aly Fahmy Mohamed, Eman Amin Ismail. Assessment of Anticancer Properties of Grape Seed Derived Procyanidin and Quercetin Against Lung (A549) and Prostate (PC-3) Cancer Cell Lines: An In-Vitro Study. Inventi Impact: Oncology, 2017(4):186-190, 2017.
    Download Full Text